The SFDA, along with other related departments, will soon kick off a one-year national campaign to regulate the drug market, said sources from the conference.

The campaign will target malpractice in drug research, production, distribution and application as well as slack supervision, according to a plan released at the conference.

Two months earlier, a fake injection produced by Qiqihar No. 2 Pharmaceutical Co. Ltd., a privately-owned business in Northeast China's Heilongjiang Province, caused 11 deaths in China.

Both companies involved in the two incidents are qualified pharmaceutical companies, and medicines produced by the two were marketed through legal channels. These facts have made the public even more worried about drug safety.

The incidents have prompted supervision departments to take more stringent measures. "More efforts should be made to check on the drug industry in areas like raw materials, production facilities, workers' qualification, and managers' awareness of their responsibilities," Shao Mingli said.